164 related articles for article (PubMed ID: 35439962)
1. Influence of data disclosures on physician decisions about off-label uses: findings from a qualitative study.
Chansky MC; Price SM; Aikin KJ; O'Donoghue AC
BMC Prim Care; 2022 Apr; 23(1):87. PubMed ID: 35439962
[TBL] [Abstract][Full Text] [Related]
2. Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
Schwartz LM; Woloshin S; Lu Z; Ross KM; Tessema FA; Peter D; Kesselheim AS
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006073. PubMed ID: 31707825
[TBL] [Abstract][Full Text] [Related]
3. Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of "off-label" prescribing.
Ghinea N; Kerridge I; Little M; Lipworth W
J Eval Clin Pract; 2017 Jun; 23(3):574-581. PubMed ID: 27859988
[TBL] [Abstract][Full Text] [Related]
4. Knowledge and perception of off-label drug use amongst prescribing physicians in a tertiary care hospital.
Kannan S; Bahl A; Khosla PP
Int J Risk Saf Med; 2015; 27(4):219-23. PubMed ID: 26756895
[TBL] [Abstract][Full Text] [Related]
5. The Law and Practice of Off-Label Prescribing and Physician Promotion.
Syed SA; Dixson BA; Constantino E; Regan J
J Am Acad Psychiatry Law; 2021 Mar; 49(1):53-59. PubMed ID: 33234538
[TBL] [Abstract][Full Text] [Related]
6. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.
Wong J; Motulsky A; Abrahamowicz M; Eguale T; Buckeridge DL; Tamblyn R
BMJ; 2017 Feb; 356():j603. PubMed ID: 28228380
[No Abstract] [Full Text] [Related]
7. Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.
Kesselheim AS; Wang B; Studdert DM; Avorn J
PLoS Med; 2012; 9(8):e1001280. PubMed ID: 22899894
[TBL] [Abstract][Full Text] [Related]
8. Physicians' use of and preferences for FDA-approved prescribing information.
Sullivan HW; Squire C; Aikin KJ; Tzeng J; Ferriola-Bruckenstein K; Brodsky E; Trentacosti AM; Johnson M
Res Social Adm Pharm; 2022 Jun; 18(6):3027-3037. PubMed ID: 34364803
[TBL] [Abstract][Full Text] [Related]
9. Drug, patient, and physician characteristics associated with off-label prescribing in primary care.
Eguale T; Buckeridge DL; Winslade NE; Benedetti A; Hanley JA; Tamblyn R
Arch Intern Med; 2012 May; 172(10):781-8. PubMed ID: 22507695
[TBL] [Abstract][Full Text] [Related]
10. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey.
Rolland B; Paille F; Fleury B; Cottencin O; Benyamina A; Aubin HJ
PLoS One; 2014; 9(6):e98062. PubMed ID: 24887094
[TBL] [Abstract][Full Text] [Related]
11. Maltese prescribers use of off-label and unlicensed medicines in children: perceptions and attitudes.
Ellul I; Grech V; Attard-Montalto S
Int J Clin Pharm; 2016 Aug; 38(4):788-92. PubMed ID: 27142871
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Awareness and Experience of Using off-label Drugs by Doctors of Clinical Specialties.
Drapkina OM; Shepel RN; Martsevich SY; Kutishenko NP; Berns SA; Bulgakova ES; Orlov DO; Belkin IA
Kardiologiia; 2021 May; 61(5):41-50. PubMed ID: 34112074
[TBL] [Abstract][Full Text] [Related]
13. No evidence or no alternative? Taking responsibility for off-label prescribing.
Ghinea N; Lipworth W; Kerridge I; Day R
Intern Med J; 2012 Mar; 42(3):247-51. PubMed ID: 22432984
[TBL] [Abstract][Full Text] [Related]
14. The discomfort caused by patient pressure on the prescribing decisions of hospital prescribers.
Lewis PJ; Tully MP
Res Social Adm Pharm; 2011 Mar; 7(1):4-15. PubMed ID: 21397877
[TBL] [Abstract][Full Text] [Related]
15. Ethical issues in new drug prescribing.
Cole LW; Kesselheim JC; Kesselheim AS
J Bioeth Inq; 2012 Mar; 9(1):77-83. PubMed ID: 23180203
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014.
Sankar A; Everhart AO; Jena AB; Jeffery MM; Ross JS; Shah ND; Karaca-Mandic P
Jt Comm J Qual Patient Saf; 2023 Sep; 49(9):458-466. PubMed ID: 37380503
[TBL] [Abstract][Full Text] [Related]
17. Off-label prescribing of stimulant medication to students: a qualitative study on the general practitioner perspective.
De Bruyn S; Wouters E; Ponnet K; Tholen R; Masquillier C; Remmen R; Van Hal G
Sociol Health Illn; 2020 Sep; 42(7):1657-1672. PubMed ID: 32767689
[TBL] [Abstract][Full Text] [Related]
18. Reasons for and frequency of off-label drug use.
Goločorbin Kon S; Iliković I; Mikov M
Med Pregl; 2015; 68(1-2):35-40. PubMed ID: 26012242
[TBL] [Abstract][Full Text] [Related]
19. Experiences with Patient Refusal of Off-Label Prescribing of Psychotropic Medications to Children and Adolescents in Japan.
Tsujii N; Saito T; Izumoto Y; Usami M; Okada T; Negoro H; Iida J
J Child Adolesc Psychopharmacol; 2016 Sep; 26(7):642-5. PubMed ID: 26103533
[TBL] [Abstract][Full Text] [Related]
20. What differentiates primary care physicians who predominantly prescribe diuretics for treating mild to moderate hypertension from those who do not? A comparative qualitative study.
Rochefort CM; Morlec J; Tamblyn RM
BMC Fam Pract; 2012 Feb; 13():9. PubMed ID: 22375684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
